385 related articles for article (PubMed ID: 27601709)
1. Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival.
Krcik EM
Radiol Technol; 2016 Sep; 88(1):123-8. PubMed ID: 27601709
[TBL] [Abstract][Full Text] [Related]
2. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
4. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
7. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
8. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
9. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
10. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
11. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
13. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
Krishnamurthy A; Jimeno A
Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290
[TBL] [Abstract][Full Text] [Related]
20. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
